ArticleCancer medicine2025
MMRN1 Facilitates Renal Cell Carcinoma by Activating AMPK/MMPs Axis.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- MMRN1 Facilitates Renal Cell Carcinoma by Activating AMPK/MMPs Axis.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMMRN1 is a metastasis-associated gene that is abnormally expressed in a variety of tumors. The present study aimed to explore the role of MMRN1 in renal cell carcinoma (RCC) and its related molecular mechanisms.
methodsRNA sequencing was used to detect differential gene expression in RCC. Immunohistochemical (IHC) analysis identified the expression of MMRN1 in RCC. Statistical evaluations and the GEPIA database were conducted to examine the association between MMRN1 expression and the prognosis of RCC patients. The MTT assay was employed to assess cellular proliferative capacity, while the Transwell assay was used to evaluate metastasis. Additionally, subcutaneous tumor transplantation and lung metastasis assays in nude mice were performed to investigate the growth and metastasis of RCC cells in vivo.
resultsMMRN1 was significantly upregulated in RCC. The GEPIA database revealed an association between MMRN1 and distal metastasis, as well as poor prognosis in RCC patients. The overexpression of MMRN1 was found to enhance the proliferation and metastasis of RCC cells, whereas MMRN1 knockout was opposite. Additionally, MMRN1 overexpression facilitated the growth and metastasis of transplanted tumors in nude mice models. Mechanistically, MMRN1 overexpression activated the AMPK signaling pathway in RCC, and inhibition of this pathway mitigated the observed effects.
conclusionMMRN1 is an oncogene in RCC. MMRN1 activates MMPs through the AMPK pathway to promote the proliferation and invasion of RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.